商业保险人群中消化系统疾病的患病率与经济负担
研究分析2016至2018年商业保险成人数据库,纳入7,297,435例消化系统疾病患者,评估38种疾病的患病率、医疗与药物费用及利用率。消化系统疾病总人群点患病率为24%,不同疾病年化总费用从10,038美元至107,007美元不等,门诊就诊占全部临床 encounters 的90%。
要点
- 消化系统疾病在商业保险成人中点患病率为24%。
- 年化总费用因疾病而异,从10,038美元至107,007美元。
- 门诊就诊占所有临床 encounters 的90%。
核心结论
- 消化系统疾病常见、费用与利用率异质性大,对美国成人群体构成显著经济负担。
研究设计与样本
- 基于2016至2018年商业保险成人理赔与支付数据的回顾性分析,覆盖38种消化系统疾病,纳入7,297,435例患者。
主要发现
- 总人群消化系统疾病点患病率为24%。
- 年化总费用按临床类别从10,038美元(嗜酸性食管炎)至107,007美元(丙型肝炎)。
- 常见疾病年化总费用:酒精性肝病39,653美元,急性胰腺炎42,554美元,克罗恩病62,735美元,功能性胃肠病13,948美元,非酒精性肝硬化53,214美元,溃疡性结肠炎36,441美元。
- 住院平均费用从12,218美元(非感染性胃肠炎/结肠炎)至78,259美元(非酒精性脂肪性肝炎)。
- 门诊就诊费用从784美元(胃肠道感染)至4,629美元(胆囊及胆道疾病),每次配药平均费用从83美元(胃食管反流病)至1,458美元(丙型肝炎)。
关键数值与推荐
- 研究期间共发生27,429,046次临床 encounters,其中90%为门诊就诊。
- 腹痛是门诊就诊和急诊科转居家 encounters 的最大单一贡献因素。
- 住院 stays 异质性更大,无单一疾病占比超过12%(胆囊及胆道疾病为12%)。
临床怎么用
- 提示临床医生关注消化系统疾病的高患病率及不同疾病间的费用差异。
- 门诊是消化系统疾病负担的主要环节,腹痛是门诊就诊的主要贡献因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Digestive diseases represent a diverse group of clinical conditions that impact the population. Their heterogeneity in classification, presentation, acuity, chronicity, and need for drug therapy presents a challenge when comparing and contrasting the burden associated with these conditions. Prior studies use an outdated classification system and aggregate costs at the population level or focus on specific diseases, limiting the ability to characterize the overall landscape. Our aim was to provide the most up-to-date assessment of cost, utilization, and prevalence associated with digestive diseases. METHODS: We examined digestive disease claims and payment data for a commercially insured adult population between 2016 and 2018 to provide a comprehensive summary of costs, utilization, and prevalence across 38 conditions. Outcome variables included point prevalence and relative prevalence, annualized all-cause medical and drug costs, digestive disease-specific average medical cost, digestive disease-specific cost per fill, and utilization by clinical setting and by clinical condition. RESULTS: A total of 7,297,435 individuals with a digestive disease diagnosis were included in the study. The point prevalence of having a digestive disease in the total population was 24%. Annualized total costs by clinical category ranged from $10,038 (eosinophilic esophagitis) to $107,007 (hepatitis C), with medical costs accounting for most of the expenditures in a majority of conditions. Annualized total costs for common conditions included $39,653 for alcoholic liver disease, $42,554 for acute pancreatitis, $62,735 for Crohn's disease, $13,948 for functional gastrointestinal disorders, $53,214 for nonalcoholic cirrhosis, and $36,441 for ulcerative colitis. Average cost of inpatient stays ranged from $12,218 (noninfectious gastroenteritis/colitis) to $78,259 (nonalcoholic steatohepatitis). Outpatient visits ranged from $784 (gastrointestinal infection) to $4629 (gallbladder and biliary tract disease). Average drug cost per fill ranged from $83 (gastroesophageal reflux disease) to $1458 (hepatitis C). A total of 27,429,046 clinical encounters occurred across all conditions during the study period, with 90% taking place as outpatient visits. Abdominal pain was the single largest contributor to outpatient visits and emergency department to home encounters. Inpatient stays were considerably more heterogeneous, with no condition accounting for more than 12% (gallbladder and biliary tract disease) of the total. CONCLUSIONS: The results demonstrate digestive diseases are common, heterogeneous in cost and utilization, and collectively exact a significant financial burden on the U.S. adult population.
引用
- Mathews SC, Izmailyan S, Brito FA, et al. Prevalence and Financial Burden of Digestive Diseases in a Commercially Insured Population. Clin Gastroenterol Hepatol. 2021. PMID: 34217877. doi:10.1016/j.cgh.2021.06.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。